BBC Homepage World Service Education
BBC Homepagelow graphics version | feedback | help
BBC News Online
 You are in: Health
Front Page 
World 
UK 
UK Politics 
Business 
Sci/Tech 
Health 
Background Briefings 
Medical notes 
Education 
Entertainment 
Talking Point 
In Depth 
AudioVideo 

Tuesday, 11 July, 2000, 17:17 GMT 18:17 UK
MS drug 'cheaper than care'
Beta interferon
Beta interferon may not be made widely available
A multiple sclerosis drug which could be banned on the NHS for being too expensive may actually be the most cost effective option in the long term, research shows.

A preliminary report by the National Institute for Clinical Excellence (Nice) leaked to the BBC last month indicated that beta interferon was unlikely to be made widely available on the NHS.

The drug is expensive - about 10,000 per patient per year - and Nice concluded that money would be better spent on other forms of treatment for MS sufferers.



Although the costs of beta interferon are high, the costs to society of caring for a patient disabled by MS are greater

PharmacoEconomics report

However, according to a report in the journal PharmacoEconomics published on Tuesday, long-term use of beta interferon may save money by slowing down the onset of the disease and cutting the costs associated with dealing with disability.

The report said: "Although the costs of beta interferon are high, the costs to society of caring for a patient disabled by MS are greater.

"If beta interferon can delay disease progression in the longer term, the economic impact would be substantial."

Misleading cost calculation

The authors, Dr Malcolm Kendrick and Dr Kian Johnson, from Macclesfield health economics analysts Interphase, say that previously the cost of beta interferon has been calculated on the assumption that its benefits do not last beyond the first two years.

This, they argue, is wrong, and that the overall cost of the drug is much less if its long-term impact is taken into consideration.

Biogen, which manufactures beta interferon, issued a statement saying: "The PharmacoEconomic study refutes the statements by Nice that the benefits of beta interferon do not justify the cost of treatment."

Users say beta interferon reduces the frequency and severity of the painful bouts.

A spokesman for the MS Society said: "Nice should be looking at all the evidence available on beta interferon.

"What they have acknowledged as being their provisional determination should be seriously reconsidered in light of all available evidence, and ideally, evidence from people with MS."

Nice chairman Sir Michael Rawlins has stressed that no final decision has been taken on beta interferon.

MS is incurable and causes the body's immune system to destroy a sheath protecting nerve cells in the brain and spinal cord, causing paralysis, pain and tremors.

Search BBC News Online

Advanced search options
Launch console
BBC RADIO NEWS
BBC ONE TV NEWS
WORLD NEWS SUMMARY
PROGRAMMES GUIDE
See also:

25 Jan 00 | Health
MS drug 'not worth the money'
30 Nov 98 | Medical notes
Multiple sclerosis
24 Jun 00 | Health
MS patients denied talks
21 Jun 00 | Health
MS patients 'denied drug'
10 Dec 99 | Health
MS drug 'should be restricted'
08 Mar 00 | Health
MS patients in Commons protest
Internet links:


The BBC is not responsible for the content of external internet sites

Links to more Health stories are at the foot of the page.


E-mail this story to a friend

Links to more Health stories